Furthermore, anti-obesity pharmacotherapies—including GLP-1 RAs—have shown promise not only in facilitating substantial and sustained weight loss but also in reducing systemic inflammation and improving comorbid metabolic conditions, such as insulin resistance and hypertension, which are prevalent in OSA populations (111, 120). The gene discussed is GCG; the disease is obstructive sleep apnea syndrome.